News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on AdAlta.
RELATED STOCKHEAD STORIES
News
In Case You Missed It: Germanium and gallium lead the pack followed by new drug data and lithium
News
ASX Small Cap Lunch Wrap: Who’s got their all-seeing eye on everything today?
Health & Biotech
ASX Health Stocks: AdAlta jumps 40pc after its fibrosis drug shows ‘potential efficacy’ in humans
News
Top 10 at 10: ASX stock jumps on the germanium, gallium bandwagon, gains 45pc
Health & Biotech
Orphan drug designation has a direct impact on drug pricing for these pharma players
Experts
CRITERION: The ASX cancer fighters with a sting in their treatment tails
Health & Biotech
ASX Health Stocks: MGC Pharma passes final hurdle before FDA submission; patents for Recce and AdAlta
News
Market Highlights: Fed comments scare the market, and 5 ASX small caps to watch on Tuesday
Health & Biotech
ASX Biotech Stocks: HitIQ nabs landmark deal with Premier League for its concussion management tech
Health & Biotech
ASX Biotech Stocks: This brain training app could catch dementia early and Brainchip nabs more patents
News
Market Highlights: US and Euro shares on six-day losing streak, and 5 ASX small caps to watch on Thursday
Health & Biotech
Twiggy’s Tattarang is getting into health tech – which ASX stocks will benefit?
News
Market highlights and 5 ASX small caps to watch on Tuesday
Health & Biotech
ASX Health Stocks: AdAlta gets patent in India, RhinoMed starts selling in Canada
News
Market Highlights and 5 ASX Small Caps to watch on Thursday
Health & Biotech
ASX Health Stocks: Cannabis biotech Emyria all set for Phase 1 clinical trial of lead CBD drug
Health & Biotech
